Bonum Therapeutics Moves to New Seattle Offices, Plans Team Expansion in Cancer Immunotherapy Push

Seattle biotech startup Bonum Therapeutics is relocating to a new office at 1150 Eastlake Ave E and plans to double its 31-person team as it pursues developing safer immunotherapy cancer drugs. Founded by CEO John Mulligan after a $250 million acquisition of his previous company Good Therapeutics by Roche, Bonum recently raised $93 million to fund its expansion.